Request for Information on CDC Procurement of Clinical Specimens

SOL #: 412026Sources Sought

Overview

Buyer

Health And Human Services
Centers For Disease Control And Prevention
CDC OFFICE OF ACQUISITION SERVICES
ATLANTA, GA, 30333, United States

Place of Performance

GA

NAICS

No NAICS code specified

PSC

No PSC code specified

Set Aside

No set aside specified

Timeline

1
Posted
Apr 23, 2026
2
Response Deadline
May 22, 2026, 2:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Centers for Disease Control and Prevention (CDC) is issuing a Request for Information (RFI) to gather market research on the procurement of clinical specimens or synthetic specimen matrices. This initiative supports the development and validation of diagnostic tests, aligning with the National Biodefense Strategy to enhance pandemic preparedness and counter biological threats. This RFI is for market research only and does not guarantee a future solicitation or award.

Scope of Information Requested

The CDC seeks comprehensive information on end-to-end solutions for specimen acquisition. Key areas of interest include:

  • Approach: Protocols for specimen collection, handling, storage, packaging, transport, and data management (e.g., CSV to Palantir). Compliance with shipping regulations (IATA, DOT, OSHA).
  • Specimen Characterization: Details on diagnostic characterization testing performed or available.
  • Human Subjects Protection: Compliance with 45 CFR Part 46 and 21 CFR Parts 50/56, including consent procedures.
  • Capability & Capacity: Organizational capabilities, available specimen types (including uncommon ones), volumes, lead times, and delivery schedules. Information on synthetic matrices.
  • Quality Systems: Systems for ensuring specimen quality, consistency, and traceability (e.g., cold chain, testing documentation).
  • Stability Data: Research supporting optimal storage conditions.
  • Safety: Confirmation of BSL-2 rated facilities.
  • Data Availability: Description of available metadata and ability to provide additional data upon request.
  • Expedited Collection: Ability to expedite specimen collection (≤72 hours) during public health emergencies.
  • Costs: Rough order of magnitude cost factors and pricing structures.

Contract & Timeline

  • Type: Sources Sought / Request for Information (RFI)
  • Set-Aside: None specified
  • Response Due: May 22, 2026, at 2:00 PM UTC (10:00 AM ET)
  • Published: April 23, 2026

Submission Requirements

Responses should not exceed 15 pages, including a cover page. The cover page must include Unique Entity Identification (UEI) numbers, Point of Contact information, Company Name and Address, NAICS code, and business size classification. Proprietary information should be minimized and clearly marked.

Contact Information

For inquiries, contact Joesph Miller at faz9@cdc.gov or 404.639.0279.

People

Points of Contact

Joesph MillerPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Sources Sought
Posted: Apr 23, 2026
Request for Information on CDC Procurement of Clinical Specimens | GovScope